Compare Stocks → What is the 72-Hour Profit Surge? (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CBAYNASDAQ:GNPXOTCMKTS:HBPCFNASDAQ:IFRXNASDAQ:MLND Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBAYCymaBay Therapeutics$32.48$32.40$7.26▼$32.50$3.73B0.324.11 million shs73 shsGNPXGenprex$2.18+2.8%$3.42$2.09▼$42.40$4.16M-0.6170,652 shs5,811 shsHBPCFHelix BioPharma$0.14$0.14$0.14▼$0.15$31.59M-0.1N/AN/AIFRXInflaRx$1.37-1.4%$1.54$1.14▼$5.20$80.67M1.27234,793 shs8,969 shsMLNDMillendo Therapeutics$3.48+1.2%$4.00$0.92▼$16.95$66.27M0.481.52 million shs289,664 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBAYCymaBay Therapeutics0.00%0.00%0.00%+41.03%+220.00%GNPXGenprex-4.07%-4.07%-22.63%-77.25%-93.38%HBPCFHelix BioPharma0.00%0.00%0.00%-5.03%-5.81%IFRXInflaRx+2.21%+10.32%-9.74%-9.74%-70.30%MLNDMillendo Therapeutics+1.16%+6.42%-4.40%-6.70%+93.33%What is Medicare Supplement Insurance? (Ad)Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. Learn More HereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBAYCymaBay Therapeutics1.0037 of 5 stars2.00.00.04.70.02.50.6GNPXGenprex4.6051 of 5 stars3.55.00.04.72.80.81.3HBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AIFRXInflaRx3.5872 of 5 stars3.85.00.00.02.51.71.3MLNDMillendo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBAYCymaBay Therapeutics2.08Hold$28.65-11.79% DownsideGNPXGenprex3.00Buy$10.00358.72% UpsideHBPCFHelix BioPharmaN/AN/AN/AN/AIFRXInflaRx3.50Strong Buy$13.50885.40% UpsideMLNDMillendo TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest IFRX, CBAY, MLND, HBPCF, and GNPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/25/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.003/22/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.002/29/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$32.502/20/2024CBAYCymaBay TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$32.502/14/2024CBAYCymaBay TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/14/2024CBAYCymaBay TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.502/14/2024CBAYCymaBay TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$25.00 ➝ $32.502/13/2024CBAYCymaBay TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral2/13/2024CBAYCymaBay TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold2/13/2024CBAYCymaBay TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$32.50(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59GNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AIFRXInflaRx$70K1,152.37N/AN/A$1.89 per share0.72MLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%5/20/2024 (Estimated)GNPXGenprex-$30.86M-$24.80N/AN/AN/AN/A-245.62%-185.50%5/27/2024 (Estimated)HBPCFHelix BioPharma-$4.69M-$0.04N/A∞N/AN/A-817.64%-308.71%6/12/2024 (Estimated)IFRXInflaRx-$46.18M-$0.86N/AN/AN/AN/A-40.10%-36.24%5/9/2024 (Estimated)MLNDMillendo Therapeutics-$36.41MN/A0.00∞N/AN/A-91.03%-72.44%N/ALatest IFRX, CBAY, MLND, HBPCF, and GNPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IFRXInflaRx-$0.20-$0.30-$0.10-$0.30N/AN/A2/28/2024Q4 2023CBAYCymaBay Therapeutics-$0.31-$0.35-$0.04-$0.35$0.42 million$0.06 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBAYCymaBay TherapeuticsN/A10.9610.96GNPXGenprexN/A2.312.31HBPCFHelix BioPharmaN/A1.461.46IFRXInflaRxN/A6.505.82MLNDMillendo TherapeuticsN/A6.396.39OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBAYCymaBay Therapeutics95.03%GNPXGenprex14.05%HBPCFHelix BioPharmaN/AIFRXInflaRx42.39%MLNDMillendo TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCBAYCymaBay Therapeutics7.00%GNPXGenprex11.54%HBPCFHelix BioPharma7.60%IFRXInflaRx16.30%MLNDMillendo TherapeuticsN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableGNPXGenprex261.91 million1.69 millionOptionableHBPCFHelix BioPharma9229.44 million212.00 millionNot OptionableIFRXInflaRx6258.88 million49.29 millionOptionableMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableIFRX, CBAY, MLND, HBPCF, and GNPX HeadlinesSourceHeadlineA lifesaving therapy for children with a rare disease is now the world’s most expensive drug, raising questions about accessmsn.com - March 20 at 4:34 PMMind Medicine sends psychedelic stocks higher after FDA status for LSD formulationmsn.com - March 7 at 1:33 PMClearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placementmarkets.businessinsider.com - January 11 at 10:32 AMWhy Is Clearmind Medicine (CMND) Stock Up 50% Today?msn.com - December 5 at 2:48 PMMaxim Group Maintains Their Buy Rating on Mind Medicine (MMED)markets.businessinsider.com - November 6 at 11:34 PMWhat to Look For in the Pipeline, Misconceptions of Drug Approvals and More of ‘What’s on the Mind’ of Jeffrey Casbergmanagedhealthcareexecutive.com - June 15 at 1:06 PMNumab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Programeagletribune.com - May 15 at 7:56 AMMindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy Participantssports.yahoo.com - May 10 at 2:53 PMExpert Ratings for Decibel Therapeuticsbenzinga.com - March 15 at 2:08 PMIterum Therapeutics plc (NASDAQ:ITRM) Q3 2022 Earnings Call Transcriptinsidermonkey.com - December 29 at 7:53 AMClearmind Medicine Announces Shareholders Meeting Resultsyahoo.com - December 29 at 7:53 AMClearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in Indiafinance.yahoo.com - June 3 at 8:33 AMDTx Pharma Appoints Michael Huang, MD as Chief Medical Officerfinance.yahoo.com - May 31 at 10:27 AMClearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorderkoin.com - May 26 at 10:15 AMClearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumptionfinance.yahoo.com - May 19 at 9:05 AMMind Medicine(MNMD) CEO Rob Barrow on Q1 2022 Results - Earnings Call Transcriptseekingalpha.com - May 16 at 4:07 PMClearmind Announces Pre-IND Meeting Date with FDAfinance.yahoo.com - May 15 at 3:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCymaBay TherapeuticsNASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.GenprexNASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Helix BioPharmaOTCMKTS:HBPCFHelix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.InflaRxNASDAQ:IFRXInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Millendo TherapeuticsNASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.